"The OBN team are disappointed to announce that Minister George Freeman who was scheduled to present an address for the BioTrinity delegation on Tuesday 25 April, is unavailable to attend the conference in person due to unavoidable parliamentary business, requiring his presence in Westminster on Tuesday 25th and Wednesday 26th April. The Minister would have loved to have supported and found the time to provide a recorded address, but this has not been possible due to a packed diary in the run up to the coronation."
Technical Update: Quantum Computing & Life Sciences David Grimm•Sonali Mohapatra•Jonathan Rohll
This session will feature a 15 minute presentation from Sonali Mohapatra, Quantum Innovation Sector Lead at the National Quantum Computing Centre (NQCC) on the potential impact that Quantum Computing will have on drug discovery. Followed by an investment update from David Grimm, Investment Director at Albion VC. David manages the UCL Technology Fund’s Computer and Physical Sciences investment team. Investing in a wide range of exciting deeptech opportunities, including Quantum Computing, Machine Learning and Data Analytics, Cleantech, Medtech, Edtech and Hardware.
There will be the opportunity for audience Q&A after the presentations.
Investment Director of UCL Technology Fund
Quantum Innovation Sector Lead at National Quantum Computing Centre
Head of Science & Entrepreneur Advocate at OBN (UK) Ltd
Keynote: Investment Trends for the Life Sciences Industry Tim Haines
Businesses across the UK have been battling against a backdrop of global economic uncertainty, exacerbated by soaring inflation, the cost-of-living crisis and rising costs over the past year. Whilst it’s been a challenging time across the board, the life sciences industry has continued to show resilience. This session will take a deep dive into what the future looks like for life sciences and predictions for 2023 and beyond.
The future growth of the life sciences sector and the achievement of ‘science superpower’ status will only be realised alongside an evolving, competitive fundraising environment and ever increasing deal activity for both seed and Series A funding that supports early stage innovation. This session will spotlight some of the latest and most interesting investment deals, looking at successes and challenges and identifying where there needs to be change in the future to ensure the right funding is available to the right companies at the right time. Our panel of industry leaders will provide a broad update on academic investments, charity collaborations, specialist seed funding as well as the perspective of an R&D company leader and identify what’s working and what needs improvement.
Investment Manager at UCL Technology Fund
Head of LifeArc Ventures at LifeArc Ventures
CEO of PhoreMost
Investment Director of UKi2S
Emma Palmer Foster
CONSULTANT at EJ Palmer Consulting
Keynote: An Update on the New Regulatory Environment Kathy Hills•Keith McDonald•Carole Pugh
This session will provide insight on the major developments in UK policy and regulation in life sciences – to include areas such as ILAP, new approaches to clinical trial regulation and some practical advice for liaising with MHRA.
Partner Corporate Tax at Penningtons Manches Cooper
Senior Director, Global Regulatory Affairs of IQVIA
General Manager at QbD
An Update on the UK Government Life Sciences Strategy George Freeman•Richard Hebdon
George Freeman, Minister of State in the Department for Science, Innovation and Technology (Please note this is a pre-recorded presentation)
This session will be introduced by Richard Hebdon, Director – Health & Life Sciences, Innovate UK, who will provide a follow up keynote on: ‘Building on Government’s Life Sciences Vision - delivering world-class impacts through business innovation’.
Minister of State (Minister for Science, Research and Innovation) at Department for Business Innovation & Skills (BIS)
Head of Health & Medicine at Innovate UK (UKRI)
Lunch & Networking
Panel: Exciting Exits • An insight into the latest collaboration, acquisitions, co-development success stories Julie Gilmore•Michael Kyriakides•David Llewellyn•James Tumbridge•Anand Ashok
During this session, our broad mix of speakers will share their thoughts and personal experiences of the latest exit trends for UK life science companies, including: • How Big Pharma is fuelling M&A activity • Strategic collaboration success stories • An update on IPOs • Long term investor commitment
Vice President and Global Head Lilly Gateway Labs at Lilly
Partner at Syncona
CEO & Co-Founder of DJS Antibodies
Barrister, Partner at Venner Shipley LLP at Venner Shipley Intellectual Property
Corporate Finance Associate Director of BDO
Panel: Building a Sustainable Business • Green Science & ESG Jim Bratherton•Chris Kimber-Nickelson•Kath Mackay•Nils Rage•Panteli Theocharous•Uma Sagaram
Kindly sponsored by Thermo Fisher Scientific
This session will address the impact that scientific innovation has on the environment, and what companies can do (and are already doing) to significantly reduce the environmental footprint of their scientific research. This panel comprises experts from all corners of the industry, from lab users, lab providers, science parks and green science innovators, who are all on a combined mission to create a culture of sustainability in science, and show that it is possible to create life-changing innovations whilst limiting the environmental impact.
Green Solutions Program Manager at Fisher Scientific UK
Development Director of MEPC
Director of Life Sciences at Bruntwood SciTech
Head of Environment, Social and Governance (ESG) at Stanhope - Oxford North
Global Vice President, Cell and Gene Therapy Strategy Lead at PPD, part of Thermo Fisher Scientific
CSO at CyanoCapture
Innovate UK Hosted Session: Investing in Innovative UK life sciences SMEs to improve global health and drive business growth Ayokunmi Ajetunmobi•Samana Brannigan•Alex Brown•Laura Dickens•Lorna Green•Ned Wakeman•Karen Spink
Innovate UK will drive transformational health innovation to improve health and economic growth in the UK. Through our flagship grant funding mechanism, Biomedical Catalyst, we help small and medium sized businesses test and develop innovative health and care solutions across life sciences, including therapeutics, medical devices, and digital health.
This session will look at how Biomedical Catalyst can help drive commercialisation and growth of health innovation across the UK.
15:00 Innovate UK's Flagship Health Funding Programme - the Biomedical Catalyst Dr Samana Brannigan, Head of Health Technologies, Innovate UK
15:15 De-risking tomorrow’s oncology innovation to maximise commercial impact: a new collaborative approach Ned Wakeman, Director and Founder, Lean Life Sciences
15:30 Panel Session: How the evolution of Biomedical Catalyst can help drive commercialisation and growth of health innovation across the UK Chair: Dr Karen Spink, Head of Medicines, Innovate UK
Panel: • Laura Dickens, Associate Director for Commercialisation, Medical Research Council • Lorna Green, Chief Executive Officer, LYVA Labs and LCR Ventures Ltd • Ayokunmi Ajetunmobi, Venture Development Director, Pioneer Group • Alex Brown, Sr. Investment Associate, 24 HayMarket • Ned Wakeman, Lean Life Sciences
Venture Development Director of Pioneer Group
Head of Health Technologies at Innovate UK (UKRI)
Senior Investment Associate at 24 Haymarket
Associate Director – Industry Partnerships of UKRI MRC
CEO of LYVA Labs and LCR Ventures
CEO & Founder of Lean Life Science Limited
Head of Medicines at Innovate UK (UKRI)
Panel: The CEO of the Future Jack O'Meara•Malcolm Silander•Kirsty Smitten•Emma Tinsley•Maina Bhaman
This session features an outstanding group of CEOs who have proven themselves to be ahead of the curve during these transformative times for the life sciences industry. During the session we’ll hear about the major changes seen in the external environment that’s impacted business operations over recent years e.g. Driving productivity through the adoption of new processes, the need for speed and simplification, driving digitisation, being open to new and varied collaboration and ensuring patient centricity remains at the heart of everything. We’ll also dig into to how each CEO has successfully inspired and led their teams during the period of ‘Great Re-imagination’ post Covid – and look at their expectations for continued change and evolution in the future.
CEO of Ochre Bio
Founder of Precision BioSearch
CEO of MetalloBio
CEO of Weatherden
Partner at Sofinnova Partners
Panel, Q&A: Big Pharma Showcase Laia Crespo•Jan-Philipp Kruse•Laura Lane•Andrew McConaghie•Alistair Henry
Kindly sponsored by Citeline
Session Overview - During this session our moderator will invite feedback from four Big Pharma major players on a range of topics including: • What are the new technologies and emerging trends that you are most excited about and believe will be most disruptive to both the pharma industry and patients in the coming years? • With an ongoing societal shift to focus on prevention rather than cure, how are Big Pharma incorporating this into their long term development strategies and reimagined business models? • How important is collaboration between big pharma, innovative R&D companies, investors, charities, and Government when tackling disease cures and treatments? Has this model of collaboration changed in recent years and what are the predictions for future relationships? • Where do you stand regarding a move towards a model of increased end-to-end strategic partnering and intensification of collaboration models with partners across the industry? Is this increased model of collaboration something you are keen to see more of? • What are the major challenges currently facing Big Pharma e.g., unpredictable supply chain, access to talent, investment into digital transformation?
Partner at Sanofi Ventures
Senior Director, Open Innovation of Bayer AG
VP at Eli Lilly & Co
Senior Writer at Citeline
Head of UK Research at UCB
Keynote: Valuation for fundraising – what you need to know Patrik Frei
CEO of Venture Valuation Inc.
Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland, the company he started in 1999 based on a collaboration with the Novartis Venture Fund, which became his first client. Since then he has been involved in over 800 valuations around the globe for investors as well as Biotech, Pharma and Medtech companies. Venture Valuation runs two additional services/businesses: 1) Biotechgate, a global business development database. 2. HelloPartnering, a leading one2one partnering software including the Biotechgate Digital Partnering event (www.digitalpartnering.com). Patrik graduated from the Business University of St. Gallen in Finance and completed his Ph.D thesis at the Swiss Federal Institute of Technology, EPFL in Lausanne. Patrik has experience as a board member of public and private companies, published numerus articles and provides valuation workshops around the world.
Panel: Inspiring Women in Life Science Jemma Contreras•Sheelagh Frame•Zahra Jawad•Carole Le Page•Debora Lucarelli
Kindly sponsored by BDO
This session has been designed to shine a light on some of the most inspiring women currently working in life sciences, with the moderator seeking to gain insight on the following questions: • Was a career in life sciences always on the cards for you? What were the main drivers and inspirations that helped get you where you are today and did you face any challenges? • What has been your proudest career moment or achievement to date? • How dramatically have you seen the landscape shift for women in life science shift during your career so far? • What are the factors that you believe make a successful team, and what has been the most powerful and impactful team that you’ve been part of during your career and why? • How important is mentorship/sponsorship in ensuring new talent is brought through the ranks? • What are your aspirations for both the impact that life sciences will have on society in the future, and your role within it? What are the key changes you would like to see within the industry?
Executive Managing Director of Syneos Health
CSO at Ubiquigent Ltd
CEO of Creasallis
Carole Le Page
Tax Partner at BDO LLP
Chief Executive Officer at Enhanc3d Genomics
Panel: The Evolving Role of the CRO Kinga Bercsenyi, PhD•Thomas Mander•Frances Murphy•Lisa Page•Bharat Chudasama
CROs play a crucial role in the research, discovery, design and development of new products coming to market, with innovative R&D companies are looking to CROs to take the role of a strategic partner to not only manage the R&D process but also to share in the commitment to the success of their clinical program This session gathers four outstanding research partner organisations to gain further insight into their service provision and unique expertise as well as insight on the following points: • How have the needs of R&D companies regarding CRO’s changed over the last 5-10 years, and what are the driving factors of this change? • What are the benefits of the new collaborative relationships? • Can you share an insight into some recent success stories, and the extent of the collaborative support services you provide? • How important are interpersonal relationship in ensuring both parties get the most out of the collaboration? • How do you think the CRO/R&D company relationship will further evolve in the future?
Kinga Bercsenyi, PhD
VP of Business Development at Arctoris
CEO of Domainex
Regional Vice President, Clinical Business Solutions EU & APAC at Precision for Medicine
Partner at Penningtons Manches Cooper LLP
Vice President, Head of Strategic Partnerships at Syneos Health
Exhibition & Networking
Exhibition & Networking
Exhibition & Networking
Exhibition & Networking
Closing Drinks for all delegates
Private Partnering Meetings
Private Partnering Meetings
Private Partnering Meetings
Private Partnering Meetings
BioTrinity Panels, Interviews & Keynotes
We aim to deliver a well-rounded programme of presentations, discussions, and debate around a variety of subject matters prevalent in the life sciences industry today. We include a mix of scientific focused topics, which either address the latest innovation and research, or matters that are popular and much talked about in the current mainstream landscape, along with pertinent updates on the financing and investment landscapes, as well as regulatory and legislative updates from leading voices and decision makers.
We cover a lot of ground, and the range is broad, but we aim to support our delegates by delivering a programme that is digestible, useful, and thought-provoking.
Each R&D spotlight will include 5 x 10 minute company presentations from the most innovative companies working in; Oncology, Infectious Diseases, Microbiome, Rare Diseases, Medtech, Neuroscience, Inflammatory Disease and Cell and Gene Therapy. If you are a company seeking Series A investment or to partner assets, BioTrinity is for you! Contact firstname.lastname@example.org
Detailed below is an outline of all of the sessions, if you have any queries then please email email@example.com